Avid Radiopharmaceuticals Company Profile

14:15 EDT 23rd June 2018 | BioPortfolio

Founded in 2004, Avid Radiopharmaceuticals, Inc. is a product-focused molecular imaging company that is a pioneer in developing radiopharmaceuticals for imaging Alzheimer's disease pathology. Two of Avid's radiopharmaceuticals are already in clinical trials, and Avid intends to make these products available to pharmaceutical companies that are seeking to develop new drugs for treatment of Alzheimer's disease. By providing a readily measured biomarker for this disease, Avid's products can facilitate testing of therapies aimed at amyloid plaques. Avid's first commercial product for the Alzheimer's diagnostic market is ready for development and will be used for positron emission tomography (PET).


3701 Market Street, 3rd Floor
United States of America


Phone: 215-966-6208

News Articles [63 Associated News Articles listed on BioPortfolio]

Avid Bioservices nets $21.8mm in FOPO

Avid Bioservices Inc. netted $21.8mm in a follow-on public offering of 10.3mm common shares (including 1.3mm overallotment shares) at $2.25. The company plans to use a part of the proceeds from the o...

Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including Bavituximab

TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered i...

Avid tapped to produce Enzyvant's rare disease candidate

It's Avid's latest move aimed at building a presence in the CDMO space.

Avid offloads Phase III mAb, becomes pureplay CDMO

Massachusetts-based Oncologie has agreed to buy Avid Bioservicesâ bavituximab in a deal worth up to $103m.

Avid CEO talks expansion, capacity and Asia

In an interview with BioPharma Dive, Avid's Roger Lias decribes the opportunities now open to the full-service biologics CDMO.

Avid raises $20m, working ‘aggressively’ to grow CDMO business

Avid Bioservices expects new contractual commitments in the coming weeks and months after raising more than $20m and completing its transition to a dedicated CDMO, says CEO.

Avid plans expansion with focus on biologics development

There is no slowdown in sight, says Avid Bioservices CEO, as the company today announces further expansion to support new client projects and optimize its novel CHO-based expression system.

Global and Chinese Radiopharmaceuticals and Stable Isotopes Industry, 2017 Market Research Report [Report Updated: 29122017] Prices from USD $3000

The 'Global and Chinese Radiopharmaceuticals and Stable Isotopes Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Radiopharmaceuticals ...

PubMed Articles [78 Associated PubMed Articles listed on BioPortfolio]

Adverse Reactions to Radiopharmaceuticals: A Survey Based on Clinical Cases Using Criteria of Systematic Review.

Adverse reactions to radiopharmaceuticals are still not reported worldwide. However, the type of reaction may be severe and cause death. A review of the literature was performed using some criteria of...

Influence of Storage Temperature on Radiochemical Purity ofTc-Radiopharmaceuticals.

The influence of effective room temperature on the radiochemical purity ofTc-radiopharmaceuticals was reported. This study was born from the observation that in the isolators used for the preparation ...

Hepatic Epithelioid Angiomyolipoma and 18F-FDG PET/CT.

Hepatic epithelioid angiomyolipoma (AML) is rare. Although generally epithelioid AML shows benign biological behavior, it can occasionally have malignant potential. In this study, we report a case of ...

FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma.

A 25-year-old man with IgA deficiency was treated with 2 months of chemotherapy and proton therapy for gastroesophageal junction adenocarcinoma. Restaging PET/CT 18 days posttherapy demonstrated 2 new...

Prostate-Specific Membrane Antigen PET/CT Incidental Finding of a Schwannoma.

We describe a case of a 73-year-old man with newly diagnosed prostate cancer referred to Ga-PSMA PET/CT for staging. A focal uptake of PSMA was visualized in the prostate compatible with primary prost...

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

Antiarrhythmics Versus Implantable Defibrillators (AVID)

To evaluate if use of an implantable cardiac defibrillator (ICD) results in reduction in total mortality, when compared with conventional pharmacological therapy, in patients resuscitated...

Combination Targeted Radiotherapy in Neuroendocrine Tumors

RESEARCH PLAN / BACKGROUND AND SIGNIFICANCE: Tumors originating from the neuroendocrine system, although relatively rare, may be life threatening. In cases where the disease has metastasi...

18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer.

18F ion is a positron emitting bone radiopharmaceuticals. The skeletal uptake of 18F relies on the exchange of hydroxyl ions in the hydroxyapatit crystal which is an indicator of bone meta...

Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy

Patients with primary head and neck squamous cell carcinoma (HNSCC) planned for treatment with radiotherapy with or without chemotherapy in curative setting will be treated with an adaptiv...

Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy

Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone. Beta-emitting radiopharm...

Companies [35 Associated Companies listed on BioPortfolio]

Avid Radiopharmaceuticals

Founded in 2004, Avid Radiopharmaceuticals, Inc. is a product-focused molecular imaging company that is a pioneer in developing radiopharmaceuticals for imaging Alzheimer's disease pathology. Two of A...

Avid Radiopharmaceuticals, Inc.

Avid Radiopharmaceuticals is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis and monitoring of maj...

Avid Bioservices, Inc.

Avid Bioservices provides a comprehensive range of cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid manufactures cGMP commercial product, as well as clinical s...

Coquí RadioPharmaceuticals Corp.

Coquí RadioPharmaceuticals Corp. is a medical isotope company, dedicated to the production of Molybdenum-99, which is used in 20 million procedures each year in the U.S. The Pu...


The Council on Radionuclides and Radiopharmaceuticals (CORAR) is an association comprised of companies in the United States and Canada who manufacture and distribute radiopharmace...

More Information about "Avid Radiopharmaceuticals" on BioPortfolio

We have published hundreds of Avid Radiopharmaceuticals news stories on BioPortfolio along with dozens of Avid Radiopharmaceuticals Clinical Trials and PubMed Articles about Avid Radiopharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Avid Radiopharmaceuticals Companies in our database. You can also find out about relevant Avid Radiopharmaceuticals Drugs and Medications on this site too.

Quick Search


Relevant Topics

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Corporate Database Quicklinks

Searches Linking to this Company Record